Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease

Table 2 Baseline characteristics of study participants compared by fibrosis category

	Minimal fibrosis (stage 0-2), n = 51	Advanced fibrosis (stage 3-4), n = 48	Total (n = 99)
Agea	52.9 ± 1.8	60.6 ± 1.6	56.7 ± 1.2
Sex (female/total) (%)	26/51 (51)	21/48 (44)	47/99 (47)
BMI	33.9 ± 1.1	34.6 ± 1.3	34.3 ± 0.8
Alc	6.12 ± 0.1	6.88 ± 0.3	6.48 ± 0.2
Diabetes (yes/total) (%)a	16/51 (31)	30/47(64)	46/98 (47)
Hypertension (yes/total) (%)	24/50 (48)	33/45 (73)	57/97 (59)
Dyslipidemia (yes/total) (%)	34/48 (71)	22/41 (50)	56/89 (63)
FIB-4a	1.63 ± 0.3	4.15 ± 0.5	2.83 ± 0.3
NAFLD fibrosis scorea	-1.33 ± 0.3	1.24 ± 0.2	-0.0996 ± 0.2

^aP < 0.005 was used to account for multiple comparisons.

Data presented as mean ± SEM. Independent two-sample t-test used for age and NAFLD fibrosis score comparisons. Wilcoxon test used for body mass index, A1c, and fibrosis-4 comparisons. The χ² test was used for sex, the presence of diabetes, the presence of hypertension, and the presence of dyslipidemia comparisons. BMI: Body mass index; FIB-4: Fibrosis-4; NAFLD: Non-alcoholic fatty liver disease.